And why the standard of care is the real issue in all fifty states, not three
By Dustin Robinson, Esq., CPA | LumaLex Law | Peptides · Telehealth · Regulatory Compliance
In mid-August 2026, within roughly a day of each other, two states published nearly identical notices about the same product category. The Mississippi State Board of Medical Licensure, Mississippi Board of Nursing, and Mississippi Board of Pharmacy issued a joint statement. The South Carolina Board of Medical Examiners issued its own.
Both said that licensed healthcare providers may not compound, administer, dispense, prescribe, supply, or recommend non-FDA-approved “research-grade” peptides to patients. Both said patient consent forms and waivers do not fix the problem. And both closed the delegation loop: Mississippi by stating that a provider may not circumvent the duty of care by permitting or delegating the purchase, administration, or dispensing of these drugs to other providers, and South Carolina by extending the prohibition to delegation to APRNs and PAs.
Alabama said the same thing on May 26, 2026. We wrote about that notice in detail here: Are Peptides Legal in Alabama? What Alabama’s Board Actually Said About “Research-Grade” Peptides. If you read the three notices side by side, the resemblance is not a coincidence. It is template language moving between boards.
Here is my view, and it is the whole point of this article: none of this is a change in the law. Not in Alabama, not in Mississippi, and not in South Carolina. These boards did not create a new prohibition. They restated an old one out loud. Because the underlying duty already exists in every state, including the standard of care and the requirement that drugs administered to patients be prescription quality and sourced from licensed facilities, prescribers in the other forty-seven states should read these notices as being about them, too.
This article covers what these notices actually did, who regulates physicians and how, what “standard of care” means as a legal matter, where physician First Amendment rights begin and end, and what prescribers and platforms should do about it now.
Who Actually Regulates a Physician?
Most of the confusion in the peptide space comes from a misunderstanding of which regulator does what.
There is no single agency that approves or disapproves a physician’s clinical decisions. Instead, there are overlapping layers, and each one can end a practice independently of the others.
1. The FDA Regulates Drugs, Not the Practice of Medicine
The FDA’s jurisdiction runs to products: their approval, manufacture, labeling, and distribution in interstate commerce. Congress and the agency have long declined to regulate how a licensed practitioner treats an individual patient. That is the foundation of lawful off-label prescribing, and it is why physicians can use an FDA-approved drug for an indication the FDA never approved.
It is worth being precise here, because the industry often overstates it. The express statutory practice-of-medicine carve-out at 21 U.S.C. § 396 is written for devices, and it protects the use of a legally marketed device. For drugs, the practice-of-medicine limitation rests on the structure of the Act and longstanding agency policy rather than a broad statutory exemption. In either case, it presupposes a lawfully marketed product.
That carve-out is narrower than the peptide market often assumes. It protects the clinical decision. It does not authorize a physician to obtain, hold, or administer a product that is itself unlawful to distribute for human use. A drug that has never been approved for any indication is not an off-label use of an approved drug. It is an unapproved new drug and, in most cases, a misbranded one.
2. State Medical Boards Regulate the License
Your license is a state-issued privilege, granted under a state medical practice act and administered by a board with statutory authority to investigate, subpoena, and discipline.
Boards do not need a new rule to act. Nearly every medical practice act contains a general standard-of-care or unprofessional-conduct provision that reaches conduct falling below what a reasonably prudent practitioner would do. That provision is the hook, and it has been on the books for decades.
Board discipline is also portable in a way malpractice verdicts are not. Adverse actions are reported to the National Practitioner Data Bank, and the Federation of State Medical Boards circulates board actions among member boards. A disciplinary action in one state routinely triggers reciprocal proceedings in every other state where the physician holds a license, and it will surface at every credentialing and payer enrollment for the rest of a career.
3. State Pharmacy Boards Regulate the Supply Chain
This is the layer the peptide industry consistently underestimates. All three notices contain the same sourcing requirement: prescription drugs, drug products, and ingredients must be purchased from an entity permitted by the state board of pharmacy. Mississippi went further and invited reports of unlicensed entities shipping into the state, pointing licensees to the board’s license verification tool.
That is not rhetoric. It is a referral channel. A pharmacy board has jurisdiction over out-of-state distributors shipping in, and it can act against them independently of anything happening to the physician.
4. Everyone Else
- The civil malpractice system. A jury, not a board, and a different remedy: money, with no requirement that a board act first.
- Your malpractice carrier. Most policies exclude experimental, investigational, or non-FDA-approved treatments. A covered claim and an excluded claim are two entirely different financial events for the physician personally.
- The FTC and state consumer protection statutes. These reach the marketing, not the medicine, and med spa and telehealth advertising is where most of the evidence lives.
- State attorneys general. Unlicensed practice, consumer protection, and unapproved-drug distribution theories, often moving faster than a board.
- Corporate practice of medicine doctrine. The non-licensee owner of a clinic or platform is not outside the blast radius. In most states, the ownership structure itself is regulated.
What “Standard of Care” Actually Means
“Standard of care” gets used loosely in this industry, usually as a synonym for “best practice.” It is a legal term with a specific meaning, and understanding it is the difference between a defensible practice and an indefensible one.
The classic formulation is this: the level of care, skill, and treatment that, in light of all relevant surrounding circumstances, is recognized as acceptable and appropriate by reasonably prudent similar healthcare providers. Four features of that definition matter here.
It Is Set by the Profession, Not by Statute
No legislature writes the standard of care. It is proved at trial or at hearing through expert testimony, informed by peer-reviewed literature, professional society guidance, manufacturer labeling, and accepted practice.
That has an uncomfortable implication for anyone waiting for a rule: the absence of a statute prohibiting something has never been a defense. The standard existed before the notice.
It Is Increasingly National, Not Local
The old “locality rule,” which measured a physician against other practitioners in the same community, has been abandoned or substantially modified in most states in favor of a national standard for a similarly situated practitioner.
That is precisely why these three notices matter outside their borders. A published position from three state boards is exactly the kind of evidence a plaintiff’s expert in Ohio, Texas, or Florida will put in front of a jury to establish what the reasonably prudent practitioner knew and should have done in 2026.
Board Notices Are Evidence of the Standard, Not the Standard Itself
These are notices and joint statements. They are not statutes, and they did not go through notice-and-comment rulemaking. A skilled defense lawyer will say exactly that. But it cuts the other way, too. Because the duty was already there, the notice does not need to be a rule to be devastating. What the notice destroys is the good-faith defense.
After August 18, no Mississippi or South Carolina licensee can credibly testify that the profession had not made its position clear. That argument was already thin in the other forty-seven states. It is now thinner.
Consent Does Not Cure a Breach
This is the single most misunderstood point in the peptide market, and all three boards addressed it head-on. Alabama and Mississippi used language that is close to word-for-word identical. Both state that a provider cannot require or permit a patient to waive the provider’s duty of care or the professional’s personal obligation to follow the law, and that consent forms purporting to identify a product as “research-grade” do not mitigate or eliminate professional or legal liability. South Carolina’s notice makes the same point.
The legal reasoning behind that is worth understanding. Informed consent governs the disclosure of risks of a treatment that is otherwise within the standard of care. It is not a waiver of the duty itself. A patient cannot consent to substandard care, because the licensure duty runs to the profession and the public, not merely to the individual patient.
The “research-grade, not for human consumption, patient acknowledges” form circulating in this industry does not do what the clinics using it believe it does. It is not a shield. It is a signed admission that the provider knew.
So Where Does RUO Peptide Administration Fall?
In my opinion, below the line, and not as a close call. Consider what a provider actually knows about a vial labeled “research use only” or “not for human consumption” that did not come from a 503A or 503B pharmacy:
- The identity of the compound is unverified by any regulated process.
- The purity is unverified, and certificates of analysis in this market have been falsified.
- Sterility and endotoxin levels are unverified for a product being injected.
- The manufacturing facility is frequently offshore and not FDA-registered.
- The label itself, written by the manufacturer, disclaims human use.
A prescriber administering that product cannot answer the most basic question a plaintiff’s lawyer will ask: what, exactly, did you put in your patient, and how do you know?
“I read the vendor’s website” is not an answer.
That is why this is a standard-of-care problem rather than merely a regulatory one, and why it is a problem in states that have said nothing at all.
Note carefully what this argument is not. It is not an argument against peptide therapy. Properly sourced compounded peptides, obtained from a state-licensed 503A or 503B facility using bulk substances that satisfy the statutory criteria, are a different question entirely.
The distinction is sourcing and verification, not the molecule.
The First Amendment Question: How Far Does Physician Speech Go?
There is one part of these notices I would push back on, and it is worth understanding precisely, because the industry tends to either overstate physician speech rights or ignore them entirely.
All three notices prohibit not only compounding, prescribing, administering, dispensing, and supplying, but also recommending. Alabama and Mississippi go a step further and expressly include advising. Recommending and advising are speech, and physician speech has real constitutional protection.
The Cases
Conant v. Walters, 309 F.3d 629 (9th Cir. 2002), is the closest analogue. The federal government had taken the position that a physician who recommended medical cannabis could lose the registration that allows them to prescribe controlled substances. A unanimous Ninth Circuit panel affirmed a permanent injunction barring the government from revoking a physician’s registration, or opening an investigation that might lead to revocation, based solely on a recommendation reflecting sincere medical judgment.
The court drew the line at aiding and abetting, and drew it narrowly: a physician aids and abets only by acting with the specific intent to provide the patient the means to acquire the substance, and merely anticipating what a patient will do after leaving the office is not enough.
Two honest caveats a careful reader should hold onto.
First, Conant is Ninth Circuit authority and binds no court in Alabama, Mississippi, or South Carolina. Second, and more importantly, the posture differs. Conant involved the federal government punishing speech about conduct that the physician’s own state had authorized, and the physicians in that case supplied nothing. A state medical board disciplining its own licensees under its own standard-of-care authority, for a product no state has authorized, is a materially different case.
Conant is a useful frame, not a safe harbor. Wollschlaeger v. Governor of Florida, 848 F.3d 1293 (11th Cir. 2017) (en banc), is the controlling physician-speech authority in the Eleventh Circuit, which covers Alabama, Mississippi, Florida, and Georgia. Applying heightened scrutiny under Sorrell v. IMS Health, the en banc court struck down the record-keeping, inquiry, and anti-harassment provisions of Florida’s Firearm Owners’ Privacy Act as content-based restrictions on physician speech, and expressly declined to decide whether strict scrutiny applied. But note what it did not do: it upheld the statute’s anti-discrimination provision, as construed to reach conduct by doctors. Even in the leading physician-speech case, the court let the state regulate what a physician does. South Carolina sits in the Fourth Circuit, so the governing authority there is different, though the direction of travel is the same.
NIFLA v. Becerra, 585 U.S. 755 (2018), matters more than most people realize. The Supreme Court declined to recognize “professional speech” as a separate category receiving reduced constitutional scrutiny. Content-based regulation of what professionals say generally gets heightened scrutiny. That is a meaningful headwind for a board attempting to prohibit a category of conversation.
Where the Line Actually Is
NIFLA preserved something important: the state may regulate professional conduct even where that regulation incidentally burdens speech. That is the seam these notices run through, and it is where I think the analysis lands.
A physician who tells a patient what BPC-157 is, what the published literature does and does not show, what the risks of the gray market are, and why they will not prescribe it, is engaged in protected speech. A board attempting to discipline that conversation would have a serious constitutional problem and, in my view, would lose.
A physician who writes an order, injects the product, hands the patient a vial, directs them to a specific vendor, or takes a margin on the sale is engaged in conduct. The First Amendment does not reach it.
And when a “recommendation” is attached to a commercial transaction the physician profits from, it also becomes commercial speech, where misleading claims receive no protection at all.
The Practical Advice
The words “advising” and “recommending” in these notices are, in my opinion, the legally weakest thing in them. If a board ever disciplined a physician solely for a conversation, that case would be worth fighting.
But understand what winning would cost. A constitutional defense is something you raise after an investigation has opened, after your license is already at stake, and after you have spent six figures. The right posture is not to be the test case.
So: talk to your patients honestly and completely about peptides, including research-use products and what is and is not known about them. Do not prescribe, dispense, administer, or supply RUO material. That includes anything labeled research use only or not for human consumption, or otherwise obtained outside the licensed pharmacy supply chain.
To be clear, this is not a statement about compounded peptides properly sourced from a licensed 503A or 503B pharmacy. Those are a separate question, addressed in the next section.
The Federal Layer: Why “Just Use a Compounding Pharmacy” Is Not Automatically the Answer
Prescribers reading these notices often conclude that routing everything through a compounding pharmacy solves the problem. It solves most of it. It does not solve all of it, and the gap is worth knowing. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a bulk drug substance used in patient-specific compounding must satisfy statutory criteria: it must comply with an applicable USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA’s 503A bulk drug substances list. It must also be accompanied by a valid certificate of analysis and be manufactured by an FDA-registered establishment.
Under FDA guidance interpreting those criteria, a reading the Alliance for Pharmacy Compounding has circulated to state boards, a substance labeled “for research use only,” “for lab use only,” or “not for human use” does not qualify. Section 503B imposes an analogous framework on outsourcing facilities.
Several of the most commercially popular peptides do not currently satisfy those criteria. FDA’s Pharmacy Compounding Advisory Committee took up seven of them on July 23 and 24, 2026. Agency reviewers recommended against including any on the 503A list, the committee’s votes are advisory and non-binding, and moving a substance onto that list requires proposed and final rulemaking measured in months to years. Additional peptides are slated for review in early 2027.
Until that process concludes, a pharmacy’s willingness to compound something is not the same as legal eligibility to compound it.
South Carolina’s notice made a related and pointed observation: some facilities are marketing semaglutide salt forms and research-grade powders that are not FDA-approved, and only prescription-quality material should be used in compounding. The salt form is not the approved active moiety. If you are running a GLP-1 program, that sentence is aimed directly at you.
The practical takeaway: verify the pharmacy’s permit in your state, and verify the substance, not just the pharmacy.
What Prescribers, Clinics, and Platforms Should Do Now
This applies whether or not your board has published anything.
- Source only from state-licensed pharmacies, and verify. Confirm the 503A or 503B facility holds a current permit in the patient’s state, using the pharmacy board’s license verification tool. Do this per state, not once.
- Verify the substance, not just the supplier. Obtain the certificate of analysis. Confirm the API is eligible for compounding and is not RUO-labeled material.
- Retire the waiver. The “research-grade” consent form does not transfer risk. It documents knowledge. Have counsel review every consent document in your stack.
- Audit your delegation chain. All three boards closed the loop that a physician cannot delegate to an APRN or PA to insulate themselves. Standing orders and protocols do not change that.
- Audit your marketing. Your website, social accounts, intake funnels, and any affiliate content are discoverable and are typically the first thing a board investigator reads. Claims made in marketing are attributed to the practice.
- Read your malpractice policy’s exclusions. Find out today, not after a claim, whether non-FDA-approved or investigational treatments are covered.
- Structure the RUO business separately from the clinical business. If you operate both an RUO peptide company and a clinical or telehealth channel, the separation needs to be corporate and operational, not just a disclaimer. Shared branding, shared customer lists, provider portals, and “clinic pricing” tiers are the facts a regulator will use to collapse the two.
- Map your states. Standard of care is measured where the patient is located. A multi-state telehealth platform inherits the most restrictive posture among its states, not the most permissive.
A Note for RUO Peptide Companies
The research-use channel and the clinical channel are governed by different rules, and a properly run RUO business is not what these notices are about. But there is a specific exposure worth naming.
Mississippi’s statement expressly invites reports of entities shipping prescription products, drugs, and ingredients into the state without the required license. South Carolina’s notice reminds licensees that purchasing from unpermitted facilities is itself a disciplinary matter. Both create a channel that runs from a disciplined prescriber back to that prescriber’s supplier.
If your RUO company sells to consumers for research purposes, that is one risk profile. If it markets to clinics, offers provider accounts or wholesale tiers, or produces content aimed at prescribers, you have moved into a different one, and your customer’s board file becomes your problem.
This is the moment to look hard at your channel strategy, your customer verification, and whether your marketing is doing something your legal position cannot support.
The Bottom Line
Three states in under three months, using language close enough in places to be word-for-word, is not three isolated events. It is a position diffusing through the state board system, and the fourth and fifth states are a matter of when rather than whether.
But that framing understates the point. The reason to care is not that your board might publish something. It is that the duty these notices describe already applies to you.
The standard of care does not wait for an announcement. It is largely national, it is proved by experts rather than statutes, and it cannot be waived by a patient signature. Administering a product labeled not for human consumption, obtained outside the licensed pharmacy supply chain, with unverified identity, purity, and sterility, is below it: in Mississippi, in South Carolina, in Alabama, and in the forty-seven states that have not yet said so.
Alabama, Mississippi, and South Carolina did not change the law. They said out loud what the law already required. The prescribers who should be most concerned are the ones whose boards have stayed quiet.
LumaLex Law advises prescribers, med spas, telehealth platforms, compounding pharmacies, and RUO peptide companies on sourcing, structuring, marketing compliance, and multi-state regulatory strategy in the peptide and GLP-1 space. If you are evaluating your exposure, contact our firm or read more about our research use peptide practice.
Related: Are Peptides Legal in Alabama? What Alabama’s Board Actually Said About “Research-Grade” Peptides
This article is for general informational purposes and does not constitute legal advice or create an attorney-client relationship. Regulatory positions in this area are changing quickly; confirm current requirements in each state in which you operate.
